Back to research
    Bioregulator

    Bronchogen (AEDL): What the Research on the Bronchial Bioregulator Shows

    October 20266 min read

    Bronchogen is the tetrapeptide Ala-Glu-Asp-Leu from the Khavinson bioregulator programme. Its sequence and origin, the proposed DNA-binding mechanism, the cell and rat studies, how it differs from Chonluten, and an honest look at the evidence.

    Quick Answer

    Bronchogen is a synthetic four amino acid peptide, Ala-Glu-Asp-Leu (AEDL), from Vladimir Khavinson's bioregulator programme, assigned to the bronchial epithelium. In cultured human embryonic bronchial cells it changed the activity of genes involved in airway epithelial differentiation, and in a rat model of chronic obstructive pulmonary disease it was associated with less damage to the airway lining. Almost all of this comes from one St Petersburg research network, and we found no controlled human trial.

    Bronchogen is one of two bioregulators assigned to the airways, alongside Chonluten, and one of the better documented members of the family. That makes it a useful test of what this literature can and cannot show.

    Sequence and identity

    Bronchogen is the tetrapeptide alanyl-glutamyl-aspartyl-leucine: Ala-Glu-Asp-Leu, or AEDL in one-letter code. That is the sequence claimed in the 2005 Russian patent that introduced it [1] and the one Khavinson's 2020 review gives for it [2]. Its molecular formula is C18H30N4O9, with a molecular weight of about 446.5.

    One inconsistency is worth knowing. Two papers from the same network, including the most detailed cell study, print the sequence as Ala-Asp-Glu-Leu (ADEL) [3, 4]. The 2020 review describes that cell study's results as work on AEDL [2], so ADEL looks like a transposition, but the two are different molecules. Anyone matching a certificate of analysis to the literature should check which of the two it states (see independent lab tests).

    Origin

    Bronchogen belongs to the second phase of Khavinson's programme, when short synthetic peptides were developed to stand in for organ extracts. The patent, filed in 2004 by the St Petersburg Institute of Bioregulation and Gerontology, covers a peptide compound for restoring the function of the respiratory organs [1]. The 2020 review adds that AEDL was detected by chromatography with mass spectrometry in Langopept, a peptide preparation from bronchial tissue, alongside Chonluten [2]. The tissue label comes from that origin, not from independent testing.

    Bronchogen and Chonluten

    The two airway bioregulators are easily confused. Chonluten is Glu-Asp-Gly (EDG), a tripeptide; Bronchogen is a tetrapeptide with alanine at the start and leucine at the end [2]. They are separate molecules with separate patents and, for the most part, separate experiments, so a result for one should not be read across to the other. Chonluten has its own research overview.

    The proposed mechanism

    As with the rest of the family, the proposal is that Bronchogen reaches the nucleus, binds DNA and changes which genes airway cells read. The direct evidence is biochemical.

    • In solution it raised the melting temperature of purified DNA by about 3 °C, consistent with binding to both strands, with no preference for AT-rich or GC-rich DNA [4].
    • In fluorescence experiments with short synthetic DNA fragments it bound preferentially to sequences containing CTG [5]. In the same paper, entry into the nucleus was shown for three other bioregulators, not for Bronchogen.
    • Spectrophotometry, viscometry and circular dichroism placed its binding in the major groove of DNA [3].
    • In ageing bronchial cell cultures, the authors suggest that changes in promoter methylation explain the age-related and peptide-related shifts in expression of two differentiation genes, NKX2-1 and SCGB1A1. Three other genes changed expression with no methylation change [6].

    These results show that the peptide can interact with DNA in a test tube, not that it selects particular genes in living lung tissue, which is the claim the model needs.

    What the studies show

    Human bronchial cells in culture

    The central study used human embryonic bronchial epithelial cells grown to early, middle and late passages, a laboratory stand-in for cell ageing. The peptide altered proliferation and survival proteins (Ki67, Mcl-1, p53), most strongly in the oldest cultures, and changed the expression of airway differentiation genes (NKX2-1, SCGB1A1, SCGB3A2, FOXA1, FOXA2) and of MUC4, MUC5AC and SFTPA1, whose reduced expression the authors link to lung disease [3]. An earlier study in the same cells reported increased expression of the differentiation factors CXCL12 and Hoxa3, which fall in late-passage cultures [7].

    Rat lung tissue and disease models

    In organ explants of lung from young and old rats it stimulated tissue growth [8]. The 2005 patent also describes rat models of bacterial pneumonia, bleomycin-induced lung fibrosis and oxygen-induced lung injury [1].

    The most disease-relevant data come from a rat model of chronic obstructive pulmonary disease, created by 60 days of intermittent exposure to nitrogen dioxide. The authors report that in rats given Bronchogen the features of the model receded: less goblet cell hyperplasia, squamous metaplasia, lymphocytic infiltration and emphysema, recovery of ciliated cells, more secretory IgA, and a less neutrophilic cell and cytokine profile in fluid washed from the lungs [9]. A second paper from the same group, in Russian, added a rise in surfactant protein B [10].

    How strong is the evidence?

    • One network. The cell, DNA and explant work comes from Khavinson's institute and close collaborators. The rat disease model papers, from the Research Institute of Pulmonology at Pavlov First St Petersburg State Medical University, do not list Khavinson, but one of their authors has co-published with his group [11], so they are connected rather than independent.
    • No human trial. Everything published is cell culture, isolated DNA, explants or rats. A 2020 review from the group describes Bronchogen as effective in obstructive lung disease but cites no clinical study for that statement [12], and we found none in PubMed.
    • Language. The patent, the 2020 review and two of the studies cited here are in Russian.
    • No replication. None of these findings has been repeated by an unconnected laboratory.

    Where Bronchogen fits

    Bronchogen shares its origin story, its proposed DNA-binding mechanism and its evidence gaps with the rest of the family. For that wider context, including how the tissue labels were assigned and what independent scientists have and have not tested, see our guide to Khavinson bioregulator peptides.

    References

    1. Khavinson VKh, et al. 2005. "Peptide compound restoring the function of respiratory organs" (in Russian). Russian patent RU 2255757. Google Patents
    2. Khavinson VKh. 2020. "Peptide medicines: past, present, future" (in Russian). Klinicheskaya Meditsina 98(3):165-177. doi:10.30629/0023-2149-2020-98-3-165-177
    3. Khavinson VKh, et al. 2014. "Peptide regulation of gene expression and protein synthesis in bronchial epithelium." Lung 192(5):781-791. PMID 25015171
    4. Monaselidze JR, et al. 2011. "Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability." Bulletin of Experimental Biology and Medicine 150(3):375-377. PMID 21240358
    5. Fedoreyeva LI, et al. 2011. "Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA." Biochemistry (Moscow) 76(11):1210-1219. PMID 22117547
    6. Ashapkin VV, et al. 2015. "Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells." Biochemistry (Moscow) 80(3):310-322. PMID 25761685
    7. Khavinson VKh, et al. 2012. "Peptides tissue-specifically stimulate cell differentiation during their aging." Bulletin of Experimental Biology and Medicine 153(1):148-151. PMID 22808515
    8. Zakutskii AN, et al. 2006. "The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats" (in Russian). Advances in Gerontology 19:93-96. PMID 17152728
    9. Kuzubova NA, et al. 2015. "Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology." Bulletin of Experimental Biology and Medicine 159(5):685-688. PMID 26468022
    10. Titova ON, et al. 2017. "Antiinflammatory and regenerative effect of peptide therapy in the model of obstructive lung pathology" (in Russian). Rossiiskii Fiziologicheskii Zhurnal imeni I.M. Sechenova 103(2):201-208. PMID 30199201
    11. Khavinson VK, et al. 2021. "Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19." Stem Cell Reviews and Reports 17(1):285-290. PMID 33575961
    12. Khavinson V, et al. 2020. "Peptides: Prospects for Use in the Treatment of COVID-19." Molecules 25(19):4389. PMID 32987757

    Frequently asked questions

    What is Bronchogen?

    Bronchogen is a synthetic tetrapeptide, Ala-Glu-Asp-Leu (AEDL), from the bioregulator research programme led by Vladimir Khavinson in St Petersburg. It was patented in Russia in 2005 as a peptide for the respiratory organs and is assigned to the bronchial epithelium. It is a research compound, not a licensed medicine in the UK.

    How is Bronchogen different from Chonluten?

    Both are assigned to the airways, and the originating group reports both from the same bronchial peptide preparation, but they are different molecules. Bronchogen is a tetrapeptide, Ala-Glu-Asp-Leu. Chonluten is a tripeptide, Glu-Asp-Gly. They have mostly been studied in separate experiments, so a finding for one should not be assumed for the other.

    Is the Bronchogen sequence AEDL or ADEL?

    The 2005 patent and most of the group's papers give Ala-Glu-Asp-Leu (AEDL). Two papers, including the 2014 cell study in Lung, print Ala-Asp-Glu-Leu (ADEL), yet the group's own review describes that study's results as work on AEDL. It looks like a transposition, but AEDL and ADEL are different molecules, so it is worth checking which one a certificate of analysis states.

    Has Bronchogen been tested in people?

    We found no controlled human trial in PubMed. The published experiments use human embryonic bronchial cells grown in culture, rat lung tissue explants and a rat model of chronic obstructive pulmonary disease. A review from the originating group describes Bronchogen as effective in obstructive lung disease without citing a clinical study for that statement.

    How strong is the evidence for Bronchogen?

    Early and narrow. The cell and DNA work comes from Khavinson's network, the rat disease model studies come from a St Petersburg pulmonology group connected to it, and nothing has been repeated by an unconnected laboratory. It is best read as a preclinical hypothesis with consistent but single-source support.

    Browse the Peptx catalogue

    Independently tested compounds, typically 99%+ purity (HPLC), factory-direct pricing. UK stock dispatches within 24 hours.

    Browse UK stock See our tested compounds

    Sold strictly for laboratory research. Not for human consumption.